IceCure Medical

Israel
Caesarea, Haifa, Israel, 3709504

Company profile

IceCure Medical company profile

IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. Founded in 2006 to advance the treatment of cancerous tumors, IceCure’s core technology is based on cryoablation. Its proprietary third-generation technology uses freezing temperatures (liquid nitrogen) to effectively destroy tumors safely, quickly, and painlessly, without the need for surgery. Commercially available in the U.S.A., Europe, Hong-Kong, Thailand, Singapore and South- Central America, its flagship system, ProSense™, uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The easy-to-use ProSense™ cryoablation procedure enables full physician control and can be performed in less than 30 minutes in the comfort of a doctor’s office. As a proven solution for the treatment of fibroadenomas (benign breast tumors), the ProSense system is also indicated for use in the fields of general surgery, oncology, gynecology and urology.

Business identity

Contact email
[email protected]
Phone number
97246230222
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2006-01-01, Year

Headquarters

Postal code
3709504
Country code
IL
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
8
Total equity funding
$72.5M
Last funding
Post IPO Equity / $10M / 2025-07-29
Last equity funding
Post IPO Equity / $10M
Investors
9
Lead investors
2
Founders
1
Articles
168
Exited on
2011-02-09

Founders and investors

Founders

Didier Toubia

Lead investors

Epoch Investment PartnersGiza Venture Capital

Investors

Alpha Capital AnstaltClover Wolf and Clover AlphaEpoch Investment PartnersGiza Venture CapitalRosario Capital LTD